The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
The UK-based development and research firm hopes to accelerate patient access to psychedelic therapies for treatment of various mental health conditions.
A leader from clinical-stage pharma firm NuCana shares promising results for its ProTides therapies and hopes the drugs can elevate outcomes for patients.
Interim data reportedly indicates Noxopharm’s Veyonda could be effective in treating cytokine storm, an inflammatory effect associated with moderate cases.
A leader from oncology trial insights and analysis specialist Inteliquet discusses how cancer studies can recover after the impact of the global pandemic.
An expert from synthetic biology tech firm Antheia offers ways to rethink current sourcing and manufacturing strategies to tackle current and future woes.
Organicell has announced the initial results from its India-based trial of the COVID-19 treatment Zofin look promising, plans to expand to more patients.
The trial technology provider and contract research organization will collaborate on tech and process solutions designed to accelerate clinical studies.
In this second part of a series on the state of clinical research, a leader from Javara lays out ideas to bring clinical research and care closer together.
The newly formed company (valued at $1.05b USD) will center on funding the firm’s decentralized trial technology platform and exploring new opportunities,
This month’s roundup of new hires, investment funding, partnerships, and other industry news includes key firms such as Clinical Ink, Medable, CPhI, and Sterling Pharma.
In the face of increasing demand for decentralized clinical trials and remote technology, the company has received funding to enable its further expansion.
The head of small-molecule business for the pharma solutions specialist talks about obstacles, and how companies can work to clear them for future success.
A leader from the clinical development services provider recommends using industry modal values to avoid protocol amendments, enrollment problems and more.
The US agency continues to keep a watchful eye over the nation’s pandemic response, issuing advice to professionals and taking action where appropriate.
